Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2− advanced breast cancer: a review Rachel A. FreedmanSara M. Tolaney Review 04 November 2017 Pages: 607 - 614
Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review Leah K. LambertLynda G. BalneavesCarolyn C. Gotay Review 06 November 2017 Pages: 615 - 633
Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors Frédérique NguyenLaura PeñaJérôme Abadie Preclinical study Open access 30 October 2017 Pages: 635 - 648
CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes Daniel KerekesDaniel W. VisscherAmy C. Degnim Preclinical study Open access 01 November 2017 Pages: 649 - 658
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial Gabe S. SonkeLowell L. HartHoward A. Burris Clinical trial Open access 22 October 2017 Pages: 659 - 669
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Luc Y. DirixIstvan TakacsErika P. Hamilton Clinical Trial Open access 23 October 2017 Pages: 671 - 686
Sensation of the autologous reconstructed breast improves quality of life: a pilot study Anouk J. M. CornelissenJop BeugelsStefania M. H. Tuinder Clinical trial Open access 25 October 2017 Pages: 687 - 695
The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel Rinat Bernstein-MolhoYael LaitmanEitan Friedman Clinical Trial 30 October 2017 Pages: 697 - 702
The value of embedding: integrated palliative care for patients with metastatic breast cancer M. RabowR. SmallH. Rugo Clinical trial 30 October 2017 Pages: 703 - 708
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain Maryam B. LustbergTonya S. OrchardLisa Yee Clinical trial 03 November 2017 Pages: 709 - 718
The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT Amy A. KirkhamNeil D. EvesKristin L. Campbell Clinical trial 06 November 2017 Pages: 719 - 729
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer Mothaffar F. RimawiCarmine De AngelisRachel Schiff Clinical trial 07 November 2017 Pages: 731 - 740
The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women’s Health Initiative observational study Cathryn H. BockAllison M. JayMichael S. Simon Epidemiology 24 October 2017 Pages: 741 - 749
Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery Rinaa S. PungliaWei JiangLaurel A. Habel Epidemiology 28 October 2017 Pages: 751 - 759
Safety of fertility preservation in breast cancer patients in a register-based matched cohort study Kenny A. Rodriguez-WallbergSandra ElorantaAnnelie Liljegren Epidemiology Open access 02 November 2017 Pages: 761 - 769
Breast cancer-related paraneoplastic neurologic disease Brittany L. MurphyNicholas L. ZalewskiElizabeth B. Habermann Epidemiology 07 November 2017 Pages: 771 - 778
Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers DG EvansEF HarknessF. Lalloo Epidemiology Open access 07 November 2017 Pages: 779 - 785
Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ Victoria SopikPing SunSteven A. Narod Epidemiology 08 November 2017 Pages: 787 - 795
Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial Catherine C. GoingLudmila AlexandrovaSharon J. Pitteri Brief Report 07 November 2017 Pages: 797 - 802
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation Rafael Canfield BrianeseKivvi Duarte de Mello NakamuraDirce Maria Carraro Brief Report 07 November 2017 Pages: 803 - 814
Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue? Kadri Altundag Letter to the Editor 11 October 2017 Pages: 815 - 815
Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically Alessandra RavaioliFabio FalciniLauro Bucchi Letter to the Editor 13 October 2017 Pages: 817 - 818
Does the elevation of CAMLs predict metastatic breast cancer patients’ survival? Qixing TanQinghong Qin Letter to the Editor 20 October 2017 Pages: 819 - 819
Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival Kadri Altundag Letter to the Editor 23 October 2017 Pages: 821 - 821
Reclassifying HER2-equivocal disease Steven Sorscher Letter to the Editor 23 October 2017 Pages: 823 - 823
